Migraine is a complex neurological disorder that affects approximately 1 billion people worldwide, making it the third most prevalent illness globally and the leading cause of disability in people under 50 years of age. Far beyond a simple headache, migraine involves a cascade of neurological events that can produce debilitating pain, sensory disturbances, and significant impairment of daily function. Despite its enormous burden, migraine remains widely underdiagnosed and undertreated. A deeper understanding of the condition empowers patients to work effectively with their healthcare providers toward better control and improved quality of life.

Migraine is classified into several subtypes based on clinical features. Migraine without aura is the most common form, accounting for approximately 70–80% of cases. It presents with moderate-to-severe unilateral (one-sided) throbbing headache lasting 4–72 hours, often accompanied by nausea, vomiting, photophobia (light sensitivity), and phonophobia (sound sensitivity). Migraine with aura affects about 25–30% of migraineurs. The aura is a reversible neurological disturbance — most commonly visual (zigzag lines, flashing lights, scotomas/blind spots) — that develops gradually over 5–20 minutes and typically lasts less than 60 minutes, usually preceding the headache. Other aura types include sensory (tingling/numbness), speech/language, motor, brainstem, and retinal. Chronic migraine is defined as headache occurring on 15 or more days per month for at least 3 months, with migraine features on at least 8 of those days. Menstrual migraine occurs in relation to the menstrual cycle, typically in the 2 days before to 3 days after the onset of menstruation, driven by estrogen withdrawal. Vestibular migraine presents primarily with episodic vertigo and may occur with or without headache.

Identifying and managing triggers is a cornerstone of migraine self-management, though it is important to recognize that triggers are not causes — they lower the threshold for an attack in a brain that is already susceptible. Common triggers include: Stress and stress let-down (the "weekend migraine" phenomenon). Sleep disturbances — both too little and too much sleep, irregular sleep schedules, and jet lag. Hormonal fluctuations — menstruation, ovulation, oral contraceptives, menopause. Dietary factors — skipping meals (most common food trigger), alcohol (especially red wine), caffeine withdrawal, aged cheeses, processed meats, MSG, and artificial sweeteners in some individuals. Environmental stimuli — bright or flickering lights, strong smells (perfumes, chemicals), weather changes, high altitude. Physical factors — intense exercise without adequate warm-up, dehydration, neck tension. Keeping a migraine diary that tracks attacks, potential triggers, food intake, sleep patterns, stress levels, and menstrual cycle is invaluable for identifying individual trigger patterns.

The goal of acute treatment is to achieve complete pain freedom within 2 hours with no recurrence within 24 hours. Timing is critical — treating early when pain is still mild (the "treat early" principle) dramatically improves outcomes. Simple analgesics and NSAIDs — ibuprofen (400 mg), naproxen (500–750 mg), and aspirin (900–1000 mg) are effective for mild-to-moderate attacks and should be used first-line. Paracetamol (1000 mg) is less effective but an option when NSAIDs are contraindicated. Triptans are the gold standard for moderate-to-severe migraine. Sumatriptan (50–100 mg oral, 6 mg subcutaneous, or nasal spray) was the first; others include rizatriptan, eletriptan, zolmitriptan, almotriptan, naratriptan, and frovatriptan. They act as serotonin 5-HT1B/1D receptor agonists, constricting dilated cranial blood vessels and inhibiting trigeminal nerve signaling. Contraindicated in patients with cardiovascular disease, uncontrolled hypertension, or hemiplegic migraine. Gepants (CGRP receptor antagonists) — rimegepant and ubrogepant are newer oral options effective for acute treatment without vasoconstrictive effects, making them suitable for patients who cannot take triptans. Ditans — lasmiditan is a selective 5-HT1F agonist that lacks vasoconstrictive properties. Anti-emetics such as metoclopramide or domperidone are useful adjuncts when nausea is prominent and also enhance absorption of oral analgesics.

Preventive treatment should be considered when migraine attacks occur ≥4 days per month, attacks are severely disabling despite optimal acute treatment, acute medications are overused or contraindicated, or the patient has uncommon migraine subtypes (hemiplegic, brainstem aura, prolonged aura). Traditional oral preventives include: Beta-blockers — propranolol (80–240 mg/day) and metoprolol (100–200 mg/day) have the strongest evidence; also beneficial for patients with comorbid anxiety or hypertension. Topiramate (50–100 mg/day) — effective but limited by cognitive side effects ("brain fog"), paresthesias, and weight loss; contraindicated in pregnancy. Amitriptyline (10–75 mg at bedtime) — particularly useful when migraine coexists with tension-type headache, insomnia, or depression. Valproate/divalproex (500–1500 mg/day) — effective but contraindicated in women of childbearing potential due to teratogenicity. Candesartan (16 mg/day) and venlafaxine (150 mg/day) are also supported by evidence. CGRP monoclonal antibodies represent a breakthrough in migraine prevention: erenumab (targets CGRP receptor), fremanezumab, galcanezumab, and eptinezumab (target CGRP ligand). These are administered as monthly or quarterly subcutaneous injections (eptinezumab is intravenous quarterly) and offer sustained efficacy with minimal side effects. OnabotulinumtoxinA (Botox, 155–195 units) injected into 31–39 sites across the head and neck every 12 weeks is approved specifically for chronic migraine.

One of the most important concepts in migraine management is medication overuse headache (MOH), also called rebound headache. It develops when acute migraine medications are used too frequently: simple analgesics on ≥15 days/month, or triptans, opioids, ergots, or combination analgesics on ≥10 days/month, for ≥3 months. MOH transforms episodic migraine into a chronic daily headache pattern, creating a vicious cycle where the treatment itself perpetuates the problem. The primary treatment is withdrawal of the overused medication — which typically causes a temporary worsening lasting 1–2 weeks — combined with initiation of preventive therapy. Bridging strategies may include a short course of corticosteroids or naproxen. Notably, gepants (rimegepant, ubrogepant) and ditans (lasmiditan) appear to carry a lower risk of MOH, though long-term data are still accumulating.

While most migraine can be managed in primary care, certain features warrant urgent medical evaluation: Thunderclap headache — sudden, severe headache reaching maximum intensity within seconds (rule out subarachnoid hemorrhage). New headache after age 50 — consider temporal arteritis. Headache with fever, stiff neck, or rash — rule out meningitis. Progressive headache worsening over weeks — consider space-occupying lesion. Headache with neurological deficits that do not resolve (unlike typical aura). First or worst headache of life. Headache triggered by cough, exertion, or Valsalva maneuver. Headache in an immunocompromised patient or patient with cancer history. These red flags can be remembered using the mnemonic SNNOOP10 (Systemic symptoms, Neurological signs, Onset sudden, Older age, Pattern change, Positional, Precipitated by Valsalva, Papilledema, Progressive, Pregnancy/postpartum, Painful eye, Post-traumatic, Pathology of immune system, Painkiller overuse).

Complementary strategies play an important role in comprehensive migraine management. Cognitive behavioral therapy (CBT) and biofeedback have strong evidence for migraine prevention and are particularly valuable for patients who prefer to minimize medication use. Mindfulness-based stress reduction (MBSR) can reduce migraine frequency and improve pain coping. Regular aerobic exercise (30–40 minutes, 3–5 times weekly) has been shown to be as effective as topiramate in reducing migraine frequency. Acupuncture has moderate evidence supporting its use as a preventive measure. Neuromodulation devices offer non-invasive options: single-pulse transcranial magnetic stimulation (sTMS), external trigeminal nerve stimulation (eTNS), non-invasive vagus nerve stimulation (nVNS), and remote electrical neuromodulation (REN). Supplements with some evidence include riboflavin (vitamin B2, 400 mg/day), magnesium (400–600 mg/day of magnesium citrate or glycinate), and coenzyme Q10 (300 mg/day).

Key medications for migraine include sumatriptan, rizatriptan, eletriptan, zolmitriptan, ibuprofen, naproxen, rimegepant, propranolol, metoprolol, topiramate, amitriptyline, erenumab, fremanezumab, and galcanezumab. For more information, explore related conditions on PillsCard: tension headache, depression, anxiety, and hypertension.